News from Creabilis, inVentiv, Omthera and Acura – People on the move
David Roblin has been appointed chief medical officer at Creabilis.
Before joining the European biotech, Roblin held leadership roles in Pfizer and Bayer across a wide range of therapy areas in research, development and commercial roles.
He was most recently senior vice president (VP) and head of research for European research and development (R&D) at Pfizer.
Eliot Forster, CEO of Creabilis, said: "It is reflection of Creabilis' potential that we have been able to attract a chief medical officer of David's caliber and reputation.
“He has vast experience not only in clinical development, but across the broader drug development pathway and pharmaceutical industry as a whole.”
inVentiv has named Mark Dmytruk as its new president.
Dmytruk boasts an expansive career in the healthcare, life sciences and diagnostics industries, including emerging and international market development.
He joins inVentiv fresh from his role as VP of finance at Athena Diagnostics.
Pfizer veteran executive Catherine Mackey has joined Genelux’s board of directors.
The former senior VP of worldwide R&D for Pfizer has 28 years of experience in the life science industry.
Aladar Szalay, chairman and CEO at Genelux said of her appointment: “In a career defined by excellence at every level, Mackey brings a unique set of skills and attributes that we believe will significantly complement and further strengthen the Genelux Board.”
New England IRB has appointed Kate Marchand and Maureen Oostendorp to its team as account executives.
Marchand comes to the company from her role as IRB coordinator at Metro West Medical Center in Framingham,Massachusetts.
Whilst Oostendorp was most recently senior IRB analyst for Spectrum Health Research.
New England IRB VP James Saunders said: “Kate and Maureen's diverse experience and commitment to human subject protection qualify them to provide strong and insightful assistance to New England IRB current and future clients.
"We look forward to Kate and Maureen's contributions to the continued growth and success of our growing IRB services."
Christian Schade is set to join Omthera in the newly created position of executive VP and CFO.
He leaves behind the role of executive VP and CFO at NRG Energy. Schade also has experience in the pharmaceutical industry, having worked for Princeton-based biopharmaceutical company Medarex.
Of his new position, Schade commented: “ I am excited about reentering the health care industry and delighted to join Omthera's management team at this exciting time in the Company's development.”
LBi Health has three new additions all from Digitas Health in Krista Bowman, David Lavietes and David Lane Fisher.
They each join the executive team for new LBi division the New York healthcare agency; launched earlier this month.
Previously VP, group director at Digitas, Bowman will take charge of the company’s largest client portfolio, as well as overseeing client services and marketing capabilities.
In his new role Lavietes will oversee business strategy and customer insight development across all LBi Health accounts.
And as group delivery director, Lane Fisher is responsible for project management, agency operations and financials.
Between them, the new additions hold an impressive resume of positions within leading companies, including Bristol-Myers Squibb, AstraZeneca, Johnson & Johnson, Roche, Pfizer, Merck, and Sanofi.
“Each member of our executive team combines deep healthcare marketing experience with a record of innovation that is so critical to helping brands succeed in a rapidly evolving marketing environment,” said managing director (MD) Gregg Fisher.
Acura has drafted David Azad onto its board of directors.
Azad is currently MD of healthcare-focused investment firm Galen Partners.
Prior to joining Galen, he was associate principal for healthcare practice McKinsey & Company.
Verastem has hired Jonathan Pachter as head of research.
Pachter – who is author of more than 40 peer-reviewed publications and inventor of numerous patents – joins the biopharmaceutical company with more than 20 years of experience in oncology discovery programs.
“Jon has been instrumental in progressing the science of EMT and cancer stem cells into the clinic,” said Robert Weinberg, Verastem co-founder and co-chair of the Scientific Advisory Board. “His ability to drive research will help Verastem deliver on the promise of new treatments for patients with incurable cancer.”
Beverly Popielarz and Marge Hoey have joined Interpublic Group as additions to its senior corporate human resources leadership.
Both move from roles within IPG to take the same job title at Interpublic; SVP, Global Director of Talent.
In her new position, Hoey will oversee the HR team for IPG corporate employees, corporate policies and the company's new HR systems.
Popielarz will oversee leadership and development, compensation and benefits.
IPG's Chief Strategy and Talent Officer Philippe Krakowsky said: “As we look to take talent management to a new level in these very dynamic times for media and marketing, it's important to put in place a team of senior leaders with a deep understanding of our business and the needs of our operating companies.”
